Breaking Barriers in PAH: Role of Novel Early Treatment Strategies

Pathological Mechanisms Underlying Vascular Changes in PH

Vasomotor Pathways Targeted by Therapies in PAH

Functional Class and Survival in PAH

NIH Registry: PAH Diagnosis (1981-1987)

French National Registry (2002-2003): PAH Still Often Diagnosed Late

Survival and PVR: Giessen PH Database

ESC/ERS Guidelines: Diagnostic Algorithm for PH

ESC/ERS Guidelines: Diagnostic Algorithm for PH (cont)

PAH Diagnostic Measures

PH Is Classified Into 5 Groups

Comprehensive Prognostic Evaluation and Risk Assessment Helps Guide Treatment

Initial Treatment of PAH

ESC/ERS Treatment Recommendations for Drug Monotherapy

Treat PAH as Aggressively as Possible

Functional Class II = Mild Disease?

Conflicting Evidence Regarding the Effectiveness of Combination Therapy in Short-Term RCTs

PAH Combination Therapies Tested in RCTs

ESC/ERS Recommendations for Sequential Drug Combination Therapy for PAH

Upfront Initial Combination Therapy

Initial Use of Ambrisentan Plus Tadalafil in PAH: The AMBITION Trial

AMBITION Trial: Primary Endpoint* Results

AMBITION Trial: Secondary Endpoint Results